Medical Policy Updates
- NewOrthognathic Surgery
- NewPatisiran (Onpattro)
- NewTriamcinolone Acetonide Extended-Release (Zilretta)
- NewArsenic Trioxoide (Trisenox)
- RevisedSite of Service for Administration for Infusion and Injectable Prescription Medications
- RevisedBelimumab (Benlysta)
- RevisedEculizumab (Soliris)
- RevisedDrug Therapy for Hereditary Angioedema [Cinryze, Berinert, Haegarda (Human C1 Inhibitor), Kalbitor (Ecallantide), Firazyr (Icatibant), Ruconest (C1 Esterase Inhibitor [Recombinant])]
- RevisedLaronidase (Aldurazyme), Galsulfase (Naglazyme), and Idursulfase (Elaprase), elosulfase alfa (Vimizim), and vestronidase alfa (Mepsevii)
- RevisedGaucher Disease Therapy
- RevisedAgalsidase Beta (Fabrazyme)
- RevisedPompe Disease Treatment with Myozyme (Alglucosidase alfa) and Lumizyme (Alglucosidase alfa)
- RevisedIntravenous Immunoglobulin (IVIG) Therapy
- RevisedImmune Globulin Subcutaneous (Vivaglobin, Hizentra, Gammagard Liquid, Gamunex-C/Gammaked, HyQvia, and Cuvitru for Subcutaneous Administration)
- RevisedAmniotic Membrane and Amniotic Fluid Injections
- RevisedBioengineered Skin and Soft Tissue Substitutes
- RevisedCopanlisib (Aliqopa)
- RevisedGene Expression Profiling for Uveal Melanoma
- RevisedGenetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
- RevisedRadiation Treatment with Lutathera (Lutetium; Lu 177 dotatate)
- RevisedColorectal Cancer Screening
- RevisedPhotodynamic Therapy for Choroidal Neovascularization
